Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Other immunomodulatory therapies in multiple sclerosis.

C H Polman1

  • 1Free University Hospital, Amsterdam, The Netherlands.

Bailliere'S Clinical Neurology
|April 2, 1999
PubMed
Summary

This review explores new immunomodulatory treatments for multiple sclerosis (MS), focusing on T-cells and macrophages. It examines successful therapies like interferon beta and copolymer-1 alongside less effective ones.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.

AJNR. American journal of neuroradiology·2016
Same author

Enhanced axonal metabolism during early natalizumab treatment in relapsing-remitting multiple sclerosis.

AJNR. American journal of neuroradiology·2015
Same author

Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.

Multiple sclerosis (Houndmills, Basingstoke, England)·2014
Same author

Detecting clinically-relevant changes in progressive multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2014
Same author

Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis.

Journal of neurology, neurosurgery, and psychiatry·2014
Same author

Structural degree predicts functional network connectivity: a multimodal resting-state fMRI and MEG study.

NeuroImage·2014

Area of Science:

  • Neuroimmunology
  • Immunotherapy
  • Multiple Sclerosis Pathogenesis

Background:

  • Multiple sclerosis (MS) is an autoimmune disease characterized by immune-mediated tissue destruction in the central nervous system.
  • T-cells and macrophages are key immune cells implicated in the immunopathogenesis of MS.
  • Understanding the immunopathogenesis is crucial for developing effective disease-modifying therapies.

Purpose of the Study:

  • To review emerging immunomodulatory and disease-modifying treatment strategies for multiple sclerosis.
  • To discuss current concepts of MS immunopathogenesis, highlighting the roles of T-cells and macrophages.
  • To evaluate recent advances in therapeutic interventions for MS.

Main Methods:

  • Literature review of immunomodulatory approaches for multiple sclerosis.
  • Analysis of current understanding of T-cell and macrophage involvement in MS.
  • Evaluation of clinical trial data for existing and experimental MS treatments.

Main Results:

  • Interferon beta and copolymer-1 have demonstrated success in modifying MS disease course.
  • Several other therapeutic interventions have shown limited or no efficacy.
  • Ongoing research focuses on targeting specific immune pathways involved in MS.

Conclusions:

  • Immunomodulatory therapies targeting T-cells and macrophages represent a promising avenue for MS treatment.
  • Continued research into MS immunopathogenesis is vital for advancing therapeutic options.
  • Personalized treatment strategies may improve outcomes for individuals with multiple sclerosis.

Related Experiment Videos